Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 with paclitaxel and carboplatin as first-line treatment for advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer
2011-001112-53Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing AMG 386 arm with Placebo arm (2 arms). Primary endpoint: Progression-free survival. Started Nov 2011; status: completed.
02
Drugs
trebananib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2011-001112-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001112-53.